Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831
- Citation:
- Clin Cancer Res vol 19 (20) 5798-5807
- Year:
- 2013
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Pharmas:
- Grants:
- U24 CA114740, CA114740, P30 CA015083, R01 CA129949, CA129949, U10 CA025224, CA25224-31
- Corr. Author:
- Authors:
- Amylou C. Dueck Monica M. Reinholz Xochiquetzal J. Geiger Kathleen Tenner Karla Ballman Robert B. Jenkins Darren Riehle Beiyun Chen Ann E. McCullough Nancy E. Davidson Silvana Martino George W. Sledge Peter A. Kaufman Leila A. Kutteh Julie Gralow Lyndsay N. Harris James N. Ingle Wilma L. Lingle Edith A. Perez
- Networks:
- Study
- NCCTG-N9831
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- trastuzumab, HER2-positive, breast cancer, MYC protein expression, disease-free survival